![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
July 3, 2024
GI Cancer Committee displays strong representation at ASCO; real-world data study nears activation; ECOG-ACRIN commends NCI's appointment of senior advisor for clinical research
July 3, 2024
The changes broaden eligibility for patients and permit more therapeutic options once enrolled in this randomized phase 3 trial, which explores the addition of radiotherapy to the usual treatment (chemotherapy) in people with esophagus and stomach cancer with limited spread
July 3, 2024
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
June 21, 2022
The Group is recognizing Dr. Eads as an exceptional medical oncologist and committed educator who is making significant research contributions as an international disease expert in neuroendocrine tumors and gastroesophageal malignancies
January 25, 2021
This phase II/III study, led by Dr. Shishir Maithel, is assessing the role of neoadjuvant therapy for patients with incidental gallbladder cancer
December 14, 2020
EA2174 will evaluate the role of perioperative immunotherapy for patients with esophageal or gastroesophageal junction adenocarcinoma